Skip to search formSkip to main contentSkip to account menu

TLC 388

Known as: TLC-388, TLC388 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

CamptothecinCamptothecin Analogue TLC388
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine…
4101 Background: Therapeutic options for metastatic poorly differentiated neuroendocrine carcinoma (NEC) after prior platinum… 
2011
2011
A phase I study of the novel DNA topoisomerase-1 inhibitor, TLC388, administered intravenously to patients with advanced solid tumors.
e13618 Background: The phase I first-in-human study of TLC388 (Lipotecan) examined the MTD, safety, anti-tumor activity and… 
2011
2011
Abstract A89: A phase I study of the novel DNA topoisomerase-1 inhibitor, TLC388 (Lipotecan®), administered intravenously to patients with advanced solid tumors.
Introduction: TLC388 (Lipotecan) is a potent Topoisomerase-1 inhibitor and it can disrupt both Sonic Hedgehog and HIF1-α pathways… 
2010
2010
Enhancement of radiation-induced DNA damage and inhibition of its repair by a novel camptothecin analog.
A novel camptothecin derivative (TLC388) with higher efficacy and reduced toxicity has been synthesized and tested as a novel… 
2010
2010
TLC388, a novel topoisomerase-1 inhibitor with antihypoxia inducible factor-1 alpha activity: A phase I and pharmacokinetic study in patients with advanced solid malignancies.
e13020 Background: To assess the feasibility of administering TLC388, a novel derivative of camptothecin with a unique… 
2009
2009
Abstract #1703: TLC388: A novel camptothecin derivative for improved cancer therapy
TLC388 Hydrochloride (TLC388 HCl) is a novel derivative of Topotecan hydrochloride (TPT HCl). It has the basic molecular… 
2009
2009
TLC388, a Novel Topotecan Derivative, as a Chemoradiosensitizer
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)